Skip to main content
SpringerLink
Log in

Anticoagulant Treatment Strategies for Atrial Fibrillation

  • Chapter
  • First Online:
Essentials of Atrial Fibrillation

  • 1755 Accesses

Abstract

A prothrombotic state is a characteristic of atrial fibrillation (AF), and the presence of AF is an independent risk factor for stroke and thromboembolism [1]. In accordance with the latest 2012 European Society of Cardiology (ESC) guidelines on AF, oral anticoagulation therapy should be considered in patients with AF who have one or more stroke risk factors [2].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

References

  1. Watson T, Shantsila E, Lip GY . Mechanisms of thrombogenesis in atrial fibrillation: Virchow’s triad revisited. Lancet. 2009;373:155-66.

    Google Scholar 

  2. Camm AJ, Lip GYH, De Caterina R, et al. 2012 focused update of the ES C Guidelines for the management of atrial fibrillation. An update of the 2010 ESC Guidelines for the management of atrial fibrillation. Eur Heart J. 2012;33:2719-2747.

    Google Scholar 

  3. Coppens M, Eikelboom JW, Hart RG, et al. The CHA2DS2-VASc score identifies those patients with atrial fibrillation and a CHADS2 score of 1 who are unlikely to benefit from oral anticoagulant therapy. Eur Heart J. 2013;34:170-176.

    Google Scholar 

  4. Friberg L, Rosenqvist M, Lip GY . Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J. 2012;33:1500-1510.

    Google Scholar 

  5. Olesen JB, Lip GY, Hansen ML, et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. Br Med J. 2011;3:42.

    Google Scholar 

  6. Boriani G, Botto GL, Padeletti L, et al; Italian AT-500 Registry Investigators. Improving stroke risk stratification using the CHADS2 and CHA2DS2-VASc risk scores in patients with paroxysmal atrial fibrillation by continuous arrhythmia burden monitoring. Stroke. 2011;42:1768-1770.

    Google Scholar 

  7. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY . A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138:1093-1100.

    Google Scholar 

  8. Fuster V, Rydén LE, Cannom DS, et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2011;123:e269-e367.

    Google Scholar 

  9. Cairns JA. Atrial fibrillation: antithrombotic therapy. In,Yusuf S, Cairns JA, Camm AJ, Fallen EL, Gersh BJ, eds. Evidence Based Cardiology. London: BMJ Books, 1998:544-552.

    Google Scholar 

  10. Aguilar MI, Hart R, Pearce LA . Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks. Cochrane Database Syst Rev. 2007;3:CD006186.

    Google Scholar 

  11. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146:857-867.

    Google Scholar 

  12. Lip GY, Edwards SJ. Stroke prevention with aspirin, warfarin and ximelagatran in patients with non-valvular atrial fibrillation: a systemic review and meta-analysis. Thromb Res. 2006;118:321-333.

    Google Scholar 

  13. Stroke prevention in Atrial Fibrillation (SPAF) Investigators. A differential effect of aspirin in prevention of stroke on atrial fibrillation. J Stroke Cerebrovasc Dis. 1993;3:181-188.

    Google Scholar 

  14. Connolly S, Pogue J, Hart R, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet. 2006;367:1903-1912.

    Google Scholar 

  15. Hart RG, Bhatt DL, Hacke W, et al CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of stroke in patients with a history of atrial fibrillation: subgroup analysis of the CHARISMA randomized trial. Cerebrovasc Dis. 2008;25:344-347.

    Google Scholar 

  16. The ACTIVE Investigators. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med. 2009;360:2066-2078.

    Google Scholar 

  17. Lip GY . The role of aspirin for stroke prevention in atrial fibrillation. Nat Rev Cardiol. 2011;8:602-606.

    Google Scholar 

  18. Contractor T, Levin V, Martinez MW, Marchlinski FE. Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation: dawn of a new era. Postgrad Med. 2013;125:34-44.

    Google Scholar 

  19. Connolly SJ, Eikelboom J, Joyner C, et al; for the AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364:806-817.

    Google Scholar 

  20. Granger CB, Alexander JH, McMurray JJV, et al; for the ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981-992.

    Google Scholar 

  21. Patel MR, Mahaffey KW, Garg J, et al; for the RO CKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883-891.

    Google Scholar 

  22. Hori M, Matsumoto M, Tanahashi N, et al; on behalf of J-RO CKET AF study investigators. Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation – the J-RO CKET AF study. Circ J. 2012;76:2104-2111.

    Google Scholar 

  23. Hankey GJ, Patel MR, Stevens SR, et al. Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of RO CKET AF . Lancet Neurol. 2012;11:315-322.

    Google Scholar 

  24. Fox KAA, Piccini JP, Wojdyla D, et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J. 2011;32:2387-2394.

    Google Scholar 

  25. Weitz JI, Connolly SJ, Patel I, et al. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost. 2010;104:633-641.

    Google Scholar 

  26. Yamashita T, Koretsune Y, Yasaka M, et al. Randomized, multicenter, warfarin-controlled Phase II study of edoxaban in Japanese patients with non-valvular atrial fibrillation. Circ J. 2012;76:1840-1847.

    Google Scholar 

  27. ClinicalTrials.gov Website. A phase 3, randomized, double-blind, double-dummy, parallel group, multi-center, multi-national study for evaluation of efficacy and safety of edoxaban (DU-176b) versus warfarin in subjects with atrial fibrillation - Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation (ENGAGE-AF TIMI-48). http://clinicaltrials.gov/ct/show/NCT00781391. Accessed September 12, 2013.

  28. Connolly SJ, Ezekowitz MD, Yusuf S, et al; for the RE -LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-1151.

    Google Scholar 

  29. Lip GY, Larsen TB, Skjøth F, Rasmussen LH . Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation. J Am Coll Cardiol. 2012;60:738-746.

    Google Scholar 

  30. Camm AJ, Kirchhof P, Lip GYH, et al. Guidelines for the management of atrial fibrillationThe Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace. 2010;12:1360-1420.

    Google Scholar 

  31. Pengo V, Legnani C, Noventa F, Palareti G; for the IS COAT Study Group. Italian Study on Complications of Oral Anticoagulant Therapy. Oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and risk of bleed. A multicenter inception cohort study. Thromb Haemost. 2001;85:418-22.

    Google Scholar 

  32. Lip GY, Karpha M. Anticoagulant and antiplatelet therapy use in patients with atrial fibrillation undergoing percutaneous coronary intervention: the need for consensus and a management guideline. Chest. 2006;130:1823-1827.

    Google Scholar 

  33. Nguyen MC, Murphy SA, Mega JL, et al. Triple therapy (TTx): ASA, thienopyridine and oral anticoagulation (OA) therapy following ST elevation myocardial infarction (STEMI): is it safe? (abstract 2221). Circulation. 2007;116(suppl II):II-483.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Putra University, Selangor, Malaysia

    Yee Guan Yap

  2. Prince Court Medical Centre, Kuala Lumpur, Malaysia

    Yee Guan Yap

  3. Division of Clinical Sciences, St George’s University of London, London, UK

    John Camm

  4. St George’s Hospital, London, UK

    John Camm

Authors
  1. Yee Guan Yap
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John Camm
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Healthcare

About this chapter

Cite this chapter

Yap, Y.G., Camm, J. (2014). Anticoagulant Treatment Strategies for Atrial Fibrillation. In: Essentials of Atrial Fibrillation. Springer Healthcare, Tarporley. https://doi.org/10.1007/978-1-907673-98-6_5

Download citation

  • DOI: https://doi.org/10.1007/978-1-907673-98-6_5

  • Published:

  • Publisher Name: Springer Healthcare, Tarporley

  • Print ISBN: 978-1-85873-438-5

  • Online ISBN: 978-1-907673-98-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation